ArticleExperimental and therapeutic medicine2026
Preventive administration of verapamil attenuates dextran sulfate sodium-induced colitis in mice.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease, is a chronic immune-mediated disorder characterized by relapsing gastrointestinal inflammation. UC is an idiopathic chronic relapsing-remitting inflammatory disorder affecting the colon, characterized by diarrhea and rectal bleeding. Verapamil, a phenylalkylamine-class L-type calcium channel blocker, has long been used to treat cardiovascular diseases such as hypertension, angina and arrhythmia. The present study aimed to investigate whether verapamil ameliorates UC symptoms in a murine model. In addition, the effects of verapamil on i) inflammatory cytokines, ii) the intestinal microbiota and iii) the intestinal mucosal barrier, all of which are implicated in UC pathogenesis, were investigated. UC was induced in mice by administering 2.5% dextran sulfate sodium (DSS) in the drinking water. Preventive oral administration of verapamil (10 mg/kg/day) initiated 7 days before DSS exposure attenuated body weight loss, diarrhea, and bloody stools in mice with DSS-induced colitis. Verapamil also reduced colonic inflammatory cytokine levels, partially reversed DSS-associated alterations in the intestinal microbiota, and preserved the expression of selected tight junction-related proteins and colonic glutathione levels. These findings suggested that verapamil may exert protective effects in this experimental model of colitis; however, further studies are needed to determine its potential clinical relevance in UC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.